BEIJING, May 7, 2010 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products, today announced its participation in the following conferences:
- Piper Jaffray Seventh Annual China Growth Conference, to be held May 13, 2010 at Le Parker Meridien in New York. The Company's CSO, Dr. Kevin Li, has been invited to speak in the panel discussion at 8:30 am ET, present at 11:00 am ET and meet with institutional investors throughout the day.
- BMC 2010 Life Sciences Summit, to be held May 17, 2010 at the Grand Hyatt hotel in New York. The Company's CSO, Dr. Kevin Li, has been invited to speak in the panel discussion at 2:00 pm ET and is scheduled to meet with institutional investors throughout the day.
- Oppenheimer 4th Annual China Dragon Call Conference, to be held May 18-20, 2010 at Oppenheimer's offices located at 300 Madison Avenue in New York. Management is scheduled to present at 1:45 pm ET on Tuesday, May 18, and meet with institutional investors throughout the day.
- Jefferies 2010 Global Life Sciences Conference, to be held June 8-11, 2010 at the Grand Hyatt in New York. Management is scheduled to present at 10:00 am ET on Tuesday, June 8, and meet with institutional investors throughout the day. A live webcast of the presentation will be available through NKBP's website at www.nkbp.com.
For further details, please contact your respective institutional sales representative.
About China Nuokang Bio-Pharmaceutical Inc.
China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hematological and cardiovascular products. The Company provides a diversified portfolio of products across more than 2,400 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, and Aiduo®, a cardiovascular stress imaging agent. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com or www.lnnk.com for more information.